QCG
NUVB icon

Quadrant Capital Group’s Nuvation Bio NUVB Stock Holding History

Quadrant Capital Group’s Portfolio NUVB Stock Details NUVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-2,853
Closed -$12.2K – 2124
2026
Q1 		$12.2K Hold
2,853
– – ﹤0.01% 2147
2025
Q4 		$25.6K Hold
2,853
– – ﹤0.01% 1912
2025
Q3 		$10.6K Buy
+2,853
New +$7.77K ﹤0.01% 2147
2025
Q2 		– Sell
-1,233
Closed -$2.17K – 2172
2025
Q1 		$2.17K Buy
1,233
+765
+163% +$1.74K ﹤0.01% 2496
2024
Q4 		$1.25K Hold
468
– – ﹤0.01% 2561
2024
Q3 		$1.07K Hold
468
– – ﹤0.01% 2586
2024
Q2 		$1.37K Hold
468
– – ﹤0.01% 2530
2024
Q1 		$1.7K Buy
+468
New +$899 ﹤0.01% 2532
2023
Q1 		– Sell
-1,072
Closed -$2.06K – 2766
2022
Q4 		$2.06K Buy
1,072
+480
+81% +$971 ﹤0.01% 2407
2022
Q3 		$1K Buy
+592
New +$1.69K ﹤0.01% 2540

Other funds holding NUVB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
DFO
Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Quadrant Capital Group's NUVB Position: Q2 2026 in Review

Quadrant Capital Group sold out of Nuvation Bio (NUVB) in Q2 2026, closing a stake of 2,853 shares — an estimated $12.2K sold.

Quadrant Capital Group first reported a position in NUVB in Q3 2022 and held it in 10 quarters. The position peaked at $25.6K in Q4 2025. 244 funds tracked by Wall St. Rank hold NUVB as of Q2 2026.

  • Quadrant Capital Group reported no remaining Nuvation Bio position as of Q2 2026 after selling out during the quarter.
  • Quadrant Capital Group sold 2,853 Nuvation Bio shares in Q2 2026, an estimated $12.2K.
  • Quadrant Capital Group first reported a position in Nuvation Bio in Q3 2022 and held it in 10 quarters.
  • Quadrant Capital Group's Nuvation Bio position peaked at $25.6K in Q4 2025.
  • 244 funds tracked by Wall St. Rank held Nuvation Bio as of Q2 2026.

Based on Quadrant Capital Group's 13F filing for Q2 2026, filed 14 Aug 2026.